SCHEMBL3049017

SCHEMBL3049017

CC(=O)C(=O)OCC(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAM P19021 3/20 0.40
TSHR P16473 3/20 0.39
THPO P40225 2/20 0.39
CTH P32929 1/20 0.39
CBS P35520 1/20 0.39
THRB P10828 1/20 0.38
GLO1 Q04760 1/20 0.34
ALDH1A1 P00352 3/20 0.33
LMNA P02545 2/20 0.33
FFAR3 O14843 2/20 0.33
SLC15A2 Q16348 1/20 0.33
HSD17B10 Q99714 1/20 0.33
EGLN1 Q9GZT9 2/20 0.32
LCK P06239 1/20 0.32
FYN P06241 1/20 0.32
MAPT P10636 1/20 0.31
ALOX15 P16050 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6278211 0.82 TSHR (0.47) PAMTSHRTHPOCTHCBS
SCHEMBL27654348 0.80 GLO1 (0.36) TSHRTHPOGLO1ALDH1A1LMNA
SCHEMBL75506 0.79 TSHR (0.52) PAMTSHRTHPOCTHCBS
SCHEMBL27707063 0.78 GLO1 (0.34) TSHRTHPOGLO1ALDH1A1LMNA
SCHEMBL27823858 0.78 GLO1 (0.34) TSHRTHPOGLO1ALDH1A1LMNA
SCHEMBL27820684 0.78 GLO1 (0.34) TSHRTHPOGLO1ALDH1A1LMNA
Ammonia Solution, Strong SCHEMBL9653768 0.77 TSHR (0.50) PAMTSHRTHPOCTHCBS
Hydrochloric Acid SCHEMBL865705 0.77 TSHR (0.50) PAMTSHRTHPOCTHCBS
SCHEMBL27931770 0.77 OR51E2 (0.32) GLO1
SCHEMBL28447552 0.77 TSHR (0.40) PAMTSHRTHPOCTHCBS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170239154-A1 PYRUVATE AND RELATED ALPHA-KETO CARBOXYLATES AS NOVEL ADJUVANTS IN THE TREATMENT OF POST TOOTH WHITENING SENSITIVITY AND THE TISSUE PROTECTIVE EFFECT OF PYRUVATE ON THE ORAL SOFT TISSUE RUSZNAK ZOLTAN (US) 2017-08-24 US claimed
US-8815946-B2 Inhibition of proliferation and fibrotic response of activated corneal stromal cells University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2014-08-26 US claimed
US-20090239947-A1 Inhibition of proliferation and fibrotic response of activated corneal stromal cells UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2009-09-24 US claimed
EP-1937316-A2 RADIOPROTECTIVE AGENTS University of Pittsburgh of the Commonwealth System of Higher Education (US) 2008-07-02 EP claimed
EP-1635806-B1 METHOD FOR TREATING ALCOHOLIC HEPATITIS UNIV PITTSBURGH (US) 2008-05-28 EP claimed
WO-2007014237-A2 RADIOPROTECTIVE AGENTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-02-01 WO claimed
US-20060223887-A1 Method for treating acute pancreatitis UNIVERSITY OF PITTSBURGH- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2006-10-05 US claimed
EP-1233767-B1 PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION XANTHUS LIFE SCIENCES INC (CA) 2006-04-12 EP claimed
EP-1635806-A2 METHOD FOR TREATING ALCOHOLIC HEPATITIS UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-03-22 EP claimed
US-20050245609-A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-11-03 US claimed
US-20050059738-A1 Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion XANTHUS LIFE SCIENCES, INC. (CA) 2005-03-17 US claimed
US-20050032891-A1 Method for treating alcoholic hepatitis UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2005-02-10 US claimed
EP-1233767-A4 PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION XANTHUS LIFE SCIENCES INC (CA) 2005-02-09 EP claimed
US-6846842-B2 Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion BETH ISRAEL DECONESS MEDICAL CENTER, INC. (US) 2005-01-25 US claimed
WO-2005004857-A1 METHOD FOR TREATING ACUTE PANCREATITIS UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-01-20 WO claimed
WO-2005002563-A2 METHOD FOR TREATING ALCOHOLIC HEPATITIS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCTION (US) 2005-01-13 WO claimed
US-20040110833-A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2004-06-10 US claimed
US-20030073743-A1 Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion XANTHUS LIFE SCIENCES, INC. (CA) 2003-04-17 US claimed
EP-1233767-A1 PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION Xanthus Life Sciences, Inc. (CA) 2002-08-28 EP claimed
WO-2001024793-A1 PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION XANTHUS LIFE SCIENCES, INC. (CA) 2001-04-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223887-A1 Method for treating acute pancreatitis PNLIP, LIPA, AMY2A PAM 351/4885TSHR 2399/4885THPO 1525/4885
US-20050245609-A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions IL1B, HMGB2, HMGB1 PAM 1991/4885TSHR 3340/4885THPO 337/4885
US-20050032891-A1 Method for treating alcoholic hepatitis ADH1A, ADH5, FABP1 PAM 707/4885TSHR 2060/4885THPO 1822/4885
US-20040110833-A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions HMGB1, HMGB2, HMGB3 PAM 1759/4885TSHR 3355/4885THPO 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.